the worldwide success rate of MDR-TB treatment is 55% and this is considered low when compared to a 60 success rate of 85% for drug-susceptible TB (DS-TB). (1) 61 Moxifloxacin, a fluoroquinolone, is one of the most important drugs for the treatment of MDR-TB(2), but 62 has also been used as an alternative to first-line anti-TB drugs if not well tolerated or suggested to 63 include in case of isoniazid resistance.(3-5) In general, the toxicity profile of moxifloxacin is rather mild, 64 though it includes concentration dependent QTc interval prolongation and, rarely, tendinopathy. The advantages of the Bayesian approach are the flexible timing of samples as the population 92 pharmacokinetic model can correct for deviations and that it takes a number of parameters into account 93 for example sex, age, and kidney function, leading to a more accurate estimation of AUC 0-24 . The 94 advantage of multiple linear regression-based LSSs is that these do not require modelling software and 95 AUC 0-24 can be easily estimated using only an equation and the measurement of drug concentrations. 96
The disadvantage is that samples must be taken exactly according to the predefined schedule and the 97 population of interest should be comparable because patient characteristics are not included in the 98 equations to estimate drug exposure.(30) 99
Pranger et al described a LSS for moxifloxacin for the first time using t=4 and 14 h post-dose samples. (21) 100 This sampling strategy can be considered unpractical to be used in daily practice. Magis-Escurra et al 101 described LSSs to simultaneously estimate AUC 0-24 of all first-line drugs together with moxifloxacin (t=1, 102 4, 6 h or t=2, 4, 6 h), but did not differentiate between patients using moxifloxacin alone and 103 6 moxifloxacin in combination with rifampicin.(20) Therefore the influence of the drug-drug interaction 104 between moxifloxacin and rifampicin, namely an increased moxifloxacin clearance, was not taken into 105 account in these LSSs. 106
Therefore, the aim of this study was to develop and validate two population pharmacokinetic models of 107 moxifloxacin (alone and with rifampicin) along with clinically feasible LSSs using the Bayesian approach 108 as well as multiple linear regression for the purpose of TDM of moxifloxacin in TB patients. 109 110 111
Results

112
Study population 113
The group with moxifloxacin alone (MFX) included pharmacokinetic profiles of 77 TB patients and the 114 group with moxifloxacin together with rifampicin (MFX+RIF) included profiles of 24 TB patients (Figure  115 1). The baseline characteristics sex, age and height were significantly different (P<0.05) between these 116 two groups (Table 1) . Additionally, the AUC 0-24 calculated with the trapezoidal rule (AUC 0-24, ref ) was 117 significantly lower and time of peak concentration (T max ) was significantly earlier in the MFX+RIF group 118 (P<0.05, Table 2 ). Several abnormal pharmacokinetic curves (e.g. delayed absorption or single aberrant 119 data point) were observed in both the MFX and MFX+RIF group. The best performing LSSs of MFX and MFX+RIF are shown in Table 5 and Table 6 , including mean 136 prediction error (MPE), root mean squared error (RMSE), and r 2 to evaluate the performance of the LSSs. 137
The performance of the LSS using t=2 and 6 h samples was evaluated as well, because this strategy is 138 currently used in many health facilities for TDM of anti-TB drugs. Table 7 and Table 8 show the best performing LSSs for MFX and MFX+RIF. The performance of the 155 frequently used LSS using t=2 and 6 h samples was evaluated as well and included in the tables. None of 156 the MFX LSSs met the acceptance criteria (RMSE<15%, MPE<5%) as bias was above 5% for all 157 combinations. For MFX+RIF, the two three-sample strategies and LSS using t=1 and 6 h samples met the 158 acceptance criteria. 159
The MFX LSS using t=0 and 4 h samples (RSME=9.25%, MPE= 6.85%, r 2 =0.957) had a comparable 160 performance to the three-sample strategies while being more clinically feasible and therefore was 161 chosen for further evaluation. In contrast to the Bayesian LSSs for MFX and MFX+RIF, a t=0 and 6 h 162 strategy was not feasible using a multiple linear regression approach as its performance In this study, we successfully developed a population pharmacokinetic model for moxifloxacin alone and 175 in combination with rifampicin. Furthermore, we developed and validated sampling strategies using the 176
Bayesian approach (MFX and MFX+RIF t=0 and 6 h) and multiple linear regression (MFX t=0 and 4 h; 177 MFX+RIF t=1 and 6 h) for both groups as well. 178
It was decided to develop two separate population pharmacokinetic models, and therefore also separate 179
LSSs, for moxifloxacin alone and in combination with rifampicin after observing a significant effect of 180 rifampicin on the pharmacokinetics of moxifloxacin. The population pharmacokinetic model of MFX+RIF 181
showed an approximately 35% higher total body clearance of moxifloxacin when compared to the MFX 182 pharmacokinetic model (Table 4) we could not differentiate between metabolic clearance and renal clearance in both population 213 pharmacokinetic models due to a small range of creatinine clearance in the study population. A relatively 214 high exposure of moxifloxacin in patients with renal insufficiency could be underestimated as renal 215 function may be overestimated and the other way around for patients with normal renal function and 216 relatively low exposures. The pharmacokinetic modelling software will fit a curve with the greatest 217 likelihood of being the actual pharmacokinetic curve based on drug concentrations at 0 and 6 h together 218 with patient characteristics and data of the entire population. However, when influence of creatinine 219 clearance is not available the software will pick a fit with average parameters, causing overestimation in 220 low AUC 0-24 and underestimation in high AUC 0-24 ranges. We decided not to validate one of the better11 performing three-sample strategies from Table 5, since we focussed on developing a clinically feasible  222 LSS with a strong preference for only 2 samples. Furthermore, we aimed to provide a simple and well 223 performing alternative LSS for MFX using multiple linear regression (t=0 and 4 h). We recommend to use 224 this LSS instead of the Bayesian LSS for MFX, particularly when low drug exposure is suspected, because 225 overestimation of AUC 0-24 can lead to sub therapeutic dosing with treatment failure and acquired drug 226 resistance as possible harmful consequence.(26, 36, 37) 227
In this study we decided to validate one LSS for each situation (Bayesian or multiple linear regression; 228 MFX or MFX+RIF), due to the significant influence of rifampicin on the pharmacokinetics of moxifloxacin 229 and so there would be a suitable LSS for every patient in each health care centre. The LSSs using multiple 230 linear regression performed rather well in our study population, but is less flexible in patients with 231 different characteristics. A Bayesian LSS is therefore preferred for patients who are not comparable to 232 our study populations as the population pharmacokinetic model is able to include some patient 233 characteristics. Clinicians are guided to the best option for TDM of moxifloxacin by following the decision 234 tree in Figure 8 . For implementation of moxifloxacin TDM using LSSs in daily practice, it would be 235 convenient to be able to use one sampling strategy for both MFX and MFX+RIF. This study showed that it 236 is possible to use t=0 and 6 h samples in a Bayesian LSS for both MFX as well as MFX+RIF and probably 237 even in a multiple linear regression LSS for MFX+RIF after successful validation. Unfortunately, a multiple 238 linear regression strategy for MFX alone using t=0 and 6 h samples was not feasible because of inferior 239 performance. Considering that TB patients are treated with a combination of multiple anti-TB drugs, one 240 single LSS suitable for all drugs of interest is the ideal situation, but unfortunately also rather challenging 241 due to the various pharmacokinetic properties of the different drugs. Others did succeed in developing a 242 LSS using multiple linear regression for simultaneously estimating exposure of all first-line drugs and 243 moxifloxacin in a small population of TB patients.(20) A 2 and 6 h post-dose sampling strategy is 244 frequently used for TDM of anti-TB drugs as it is believed to be able to estimate C max as well as to detect 245 12 delayed absorption.(31) However, better performances were found for the LSSs proposed in this study, 246
although the 2 and 6 h LSS performed within acceptable limits as well in the Bayesian approach and the 247 multiple linear regression. 248
In general, we noticed large inter-individual pharmacokinetic variation in terms of moxifloxacin 249 concentrations (Figure 1 ), C max , and AUC 0-24 (Table 2) as described earlier,(18) but also in K a and CL/F 250 (Table 4) LSSs could be considered as another limitation. However, we were able to collect a large dataset to 264 develop the model and clinically feasible LSSs using a sufficient number of pharmacokinetic profiles. A 265 strength of our study was that a large part of our dataset consisted of drug concentrations which were 266 collected as part of daily routine TDM. During visual check of the data we noticed several abnormal 267 curves (both MFX and MFX+RIF) that for instance showed delayed absorption with T max values of 4-6 h. 268
These curves were not excluded from the study. The models and LSSs appeared to be able to adapt to 269 on May 8, 2019 by guest http://aac.asm.org/ Downloaded from 13 this delayed absorption. In most cases, the subsequent decision to either increase the dose or not was 270 similar. For these reasons, we expect the results as reported in this study to represent the clinical 271 practice of TDM using these LSSs very closely. The small sample size of the MFX+RIF group can be 272 considered as a limitation as well, although comparable to previously published LSS studies.(21, 38-41) 273
We consider this sample size as sufficient for exploratory objectives, since this is the first study that 274 developed separate LSSs for moxifloxacin alone and in combination with rifampicin. Future research can 275 build on the results described in this study. 276
In conclusion, we developed and validated two separate pharmacokinetic models for moxifloxacin alone 277 and in combination with rifampicin in TB patients. We provided data to show significant differences in 278 drug clearance and drug exposure between these groups. Furthermore, we developed and validated LSS 279 based on the Bayesian approach (MFX and MFX+RIF 0 and 6 h) and multiple linear regression (MFX 0 and 280 4 h; MFX+RIF 1 and 6 h) that can be used to perform TDM on moxifloxacin in TB patients. 12, 18 and 24 h after drug intake. 297
As steady state is reached within 3-5 days of treatment with moxifloxacin, all data was collected during 298 steady state conditions.(11) In general, no informed consent was required, due to the retrospective 299 nature of the study. 300
The total study population was split in two groups; patients that received moxifloxacin alone (MFX) and 301 patients that received moxifloxacin together with rifampicin (MFX+RIF), because of the pharmacokinetic 302 drug-drug interaction between rifampicin and moxifloxacin. The final models were internally validated using 11 different (n-7) sub models for MFX and 12 (n-2) sub 338 models for MFX+RIF, each leaving out randomly chosen pharmacokinetic curves. All pharmacokinetic 339 
